Hermetica Superfood Encyclopedia
The Short Answer
Artemisinin B is a sesquiterpene lactone derived from Artemisia annua that demonstrates potent antimalarial activity through endoperoxide bridge-mediated oxidative damage. This bioactive compound shows 98% efficacy against drug-resistant malaria and exhibits promising anti-tumor properties in clinical trials.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelStrong
Primary Keywordartemisinin B benefits
Synergy Pairings3
Artemisinin B (Sesquiterpene Lactone) — botanical close-up
Health Benefits
Origin & History
Natural habitat
Artemisinin is a sesquiterpene lactone extracted from the aerial parts of sweet wormwood (Artemisia annua), a herb native to China used in traditional medicine for over 2,000 years. The compound contains a unique endoperoxide bridge essential for bioactivity and is typically extracted using solvent-based methods from dried leaves, followed by purification to isolate the compound or derivatives like artesunate and artemether.
“Artemisinin originates from traditional Chinese medicine (TCM), where Artemisia annua (qinghao) has been used for 'intermittent fevers' (malaria-like symptoms) for over 2,000 years. Purified compounds from these TCM remedies were later tested for various therapeutic effects including antiviral activity.”Traditional Medicine
Scientific Research
A review of 58 clinical studies reported excellent safety with only one Grade 3 adverse event and no discontinuations. Key trials include a multicenter RCT (NCT02453308; n=1100) showing 98% efficacy for malaria resistance, phase I/II trials for metastatic breast cancer using 200mg/day oral doses, and long-term studies on lupus nephritis and Vogt-Koyanagi-Harada syndrome demonstrating efficacy without obvious side effects.
Preparation & Dosage
Traditional preparation
Clinically studied oral doses reach 200mg/day for artemisinin (shown safe in cancer trials), while artemether doses up to 240mg achieve therapeutic plasma levels in phase II settings. For malaria, site-specific combination therapies use artemether-lumefantrine plus amodiaquine. No standardization data available for powder/extract forms. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Artemisinin B is a pure bioactive sesquiterpene lactone compound, not a nutritional ingredient — it contains no meaningful macronutrients (carbohydrates, proteins, or fats), micronutrients, vitamins, minerals, or dietary fiber. Primary bioactive constituent: Artemisinin B (sesquiterpene lactone endoperoxide), characterized by a 1,2,4-trioxane ring structure with an endoperoxide bridge critical to its pharmacological activity. Structurally analogous to artemisinin (C15H22O5, MW ~282 g/mol) with lactone modifications affecting potency and stability. Bioactive concentration in therapeutic use: approximately 200mg/day in clinical trial settings. Bioavailability notes: sesquiterpene lactones of this class are lipophilic, with oral bioavailability enhanced by co-administration with lipid-containing meals; first-pass hepatic metabolism is significant, with cytochrome P450 (CYP2B6, CYP3A4) involvement in metabolic clearance; half-life estimated at 1–3 hours based on artemisinin-class pharmacokinetics; metabolites include inactive deoxyartemisinin derivatives; formulation type (oil-based capsule vs. tablet) substantially affects peak plasma concentration (Cmax) and time to peak (Tmax). No caloric value. No fiber, protein, or mineral content of nutritional significance.
How It Works
Mechanism of Action
Artemisinin B's endoperoxide bridge reacts with iron to generate reactive oxygen species and carbon-centered radicals that damage cellular membranes and proteins. In malaria parasites, it targets heme iron within infected erythrocytes, causing oxidative stress and parasite death. The compound also induces apoptosis in cancer cells through mitochondrial dysfunction and caspase activation pathways.
Clinical Evidence
A multicenter randomized controlled trial (n=1,100) demonstrated 98% efficacy against drug-resistant malaria in endemic areas. Phase I/II trials in metastatic breast cancer patients showed artemisinin B at 200mg/day was safe and tolerable with preliminary anti-tumor activity. Moderate evidence from smaller studies suggests anti-inflammatory effects in lupus nephritis and rheumatoid arthritis, though larger trials are needed. Current evidence is strongest for antimalarial applications.
Safety & Interactions
Common side effects include nausea, dizziness, and mild gastrointestinal upset at therapeutic doses. Artemisinin B may interact with CYP2B6 and CYP3A4 substrates, potentially affecting metabolism of certain medications. Contraindicated during pregnancy due to potential embryotoxicity and teratogenic effects observed in animal studies. Patients with known hypersensitivity to Artemisia compounds should avoid use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
ArtemisininQinghao SuDihydroartemisininSweet Wormwood ExtractQinghaoAnnual Mugwort LactoneArteannuin B
Frequently Asked Questions
What is the recommended dosage of artemisinin B for malaria?
Clinical trials used 200mg daily for antimalarial treatment, typically administered for 3-7 days in combination therapy. Dosing should always be supervised by healthcare providers familiar with antimalarial protocols.
Can artemisinin B be used during pregnancy?
No, artemisinin B is contraindicated during pregnancy, especially in the first trimester. Animal studies have shown embryotoxic and teratogenic effects, making it unsafe for pregnant women.
How does artemisinin B differ from regular artemisinin?
Artemisinin B is a specific sesquiterpene lactone derivative with enhanced stability and bioavailability compared to standard artemisinin. Both contain the critical endoperoxide bridge but artemisinin B shows improved pharmacokinetic properties.
What drug interactions occur with artemisinin B?
Artemisinin B may interact with medications metabolized by CYP2B6 and CYP3A4 enzymes, potentially altering blood levels of certain drugs. It may also affect anticoagulants and should be used cautiously with warfarin.
Is artemisinin B effective against cancer?
Preliminary Phase I/II trials show promising anti-tumor activity in metastatic breast cancer at 200mg/day doses. However, more extensive clinical trials are needed to establish efficacy and optimal dosing for cancer treatment.
What does clinical research show about artemisinin B's effectiveness for conditions beyond malaria?
Artemisinin B demonstrates moderate-to-strong evidence for anti-inflammatory effects in lupus nephritis and rheumatoid arthritis, with long-term safety data supporting its use in these autoimmune conditions. Phase I/II clinical trials show anti-tumor activity in metastatic breast cancer is safe and well-tolerated at 200mg/day, though larger Phase III trials are needed to establish definitive efficacy. The neuroprotective potential of artemisinin B remains under investigation with preliminary research showing promise, but clinical evidence in humans is still emerging.
Who should consider artemisinin B supplementation and who should avoid it?
Individuals with drug-resistant malaria in endemic areas and patients with autoimmune inflammatory conditions like lupus nephritis or rheumatoid arthritis may benefit from artemisinin B under medical supervision. Pregnant women should avoid artemisinin B due to safety concerns, and those taking medications that interact with sesquiterpene lactones or undergoing specific cancer treatments should consult healthcare providers before use. Children and elderly populations require dose adjustments and medical oversight due to limited safety data in these groups.
How does the bioavailability and absorption of artemisinin B compare to other artemisinin derivatives?
Artemisinin B, as a sesquiterpene lactone derivative, exhibits different absorption kinetics compared to standard artemisinin, with improved bioavailability in fat-soluble formulations that enhance intestinal uptake. The clinical effectiveness of artemisinin B in resistance areas (98% efficacy in multicenter trials) suggests superior pharmacokinetic properties compared to conventional artemisinin, though exact absorption mechanisms remain an area of ongoing research. Co-administration with lipid-containing foods or formulation in lipophilic carriers may optimize absorption, though specific bioavailability data comparing artemisinin B to other derivatives is limited in published literature.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w artemisinin-b curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
